February 13, 2017
Allergan buys medical aesthetics specialist Zeltiq for $2.475 billion
Allergan has made another acquisition deal in expanding its medical aesthetics portfolio by buying Zeltiq Aesthetics for $2.475 billion.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
February 13, 2017
Anavex appoints Peter Donhauser to its Board
Anavex Life Sciences, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, has appointed Peter Donhauser, D.O. to its Board of Directors.
February 13, 2017
Pharmaceutical grade silica gel market could worth $71.05 million by 2025
The global pharmaceutical grade silica gel market is projected to reach a market size of $71.05 million by 2025.
February 13, 2017
Acacia Pharma’s PONV drug Baremsis meets goals, next step submitting to the FDA
Acacia Pharma Group has made final pivotal Phase 3 study testing amisulpride injection Baremsis, formerly APD421, for patients with post-operative nausea & vomiting (PONV), after getting antiemetic prophylaxis, and now all phases met primary endpoints.
February 13, 2017
Orion finds replacement for its retiring Senior Vice President for Research and Development in Eli Lilly
Orion Group has announced that Dr. Reijo Salonen, M.D., Ph.D., Senior Vice President for Research and Development of the Orion Group and member of the Executive Management Board of the Orion Group will step aside from his current positions as of 21 February 2017.
February 13, 2017
Hikma won exclusive licensing and distribution agreement for pulmonary disease drug
Hikma Pharmaceuticals has signed an exclusive licensing and distribution agreement with Orion Corporation of Finland (Orion), for its new Easyhaler combination product, a dry powder inhaler (DPI) of budesonide and formoterol, for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
February 13, 2017
Stada, Enzymatica in marketing deal for ColdZyme in Germany
As German generics drugmaker Stada confirmed receiving offers to be bought out, it has simultaneously made a deal with a Sweden-based life science company Enzymatica, to sell its common cold mouth spray ColdZyme in Germany.
February 13, 2017
Ipsen acquires Sanofi’s five products for €83M
Ipsen has entered into a definitive agreement to acquire Sanofi’s five consumer healthcare products in certain European territories.
February 13, 2017
Verona Pharma 10million newly consolidate ordinary shares
Verona Pharma said on Monday that, after the 50 for 1 share consolidation approved by shareholders on 8 February 2017, it now has 51,361,064 ordinary shares of £0.05 each in issue, each carrying one voting right.
February 13, 2017
Oxford BioDynamics welcomes Dr Claudio Carini to its Scientific Advisory Panel
Oxford BioDynamics, a biotechnology company focused on the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry, has appointed Dr Claudio Carini as an Advisor, effective immediately.